FLT3 mutations as diagnostic and prognostic biomarkers in acute myeloid leukemia
Genetic tests for a common leukemia mutation now guide diagnosis, prognosis, and treatment response monitoring, improving clinical decision-making when interpreted thoughtfully.
This comprehensive review synthesizes the diagnostic, prognostic, predictive, and MRD-monitoring roles of FLT3 mutations in AML, with emphasis on laboratory implementation including PCR, fragment analysis, NGS, and ddPCR. It provides a clinical laboratory perspective on interpreting FLT3 as a multi-dimensional biomarker rather than a binary mutation flag, particularly relevant for ELN 2022 integration.
What the study was
- Study design
- Narrative review
- Population
- AML patients with FLT3 mutations
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Clin Chim Acta
Why it surfaced
Practical clinical laboratory review for FLT3 in AML. Well-timed with ELN 2022 integration. Value as reference/synthesis piece for pipeline.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.